Thanks for your interest in this podcast. Please read this important program information before listening. Access to the post-test and to claim credit for participating is included below.
Activity Overview
This PER® Spectives™ podcast features a discussion among 3 optometrists on challenges and unmet needs associated with traditional treatments for meibomian gland dysfunction (MGD)-related dry eye disease (DED) — and opportunities for MGD treatment that may come with new and emerging topical therapies. In addition, the panel discusses myths and misconceptions that may affect outcomes in patients with MGD-DED. This program is designed to help clinicians better appreciate the impact of
MGD-DED on patients and optimize the growing toolkit of available therapies.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.25 AMA
PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Educational Grant Support
This activity is supported by an educational grant from Bausch + Lomb.
Target Audience
This educational activity will be targeted to practitioners who are involved in treating patients with MGD, such as Optometrists, Ophthalmologists, NPs, PAs, and nurses.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
• Analyze key trial data and real-world evidence surrounding current treatments for MGD-associated
DED
• Evaluate key clinical trial data for emerging agents being studied for the potential treatment of MGD-associated DED
Faculty:
Mile Brujic, OD, FAAO
Partner
Premier Vision Group
Bowling Green, OH
Disclosures: Advisory/Research Support: ABB Optical, Alcon Laboratories, Allergan, Art Optical, Bausch +
Lomb Health, Contamac, CooperVision, CSEye, Horizon Therapeutics, Johnson & Johnson Vision Care,
Kala, Novartis, Optovue, Oyster Point, RVL, Sun Pharma, Tarsus, Tangible Science, Santen, Walman
Optical, ZeaVision
David Kading, OD, FAAO, FCLSA
CEO/Owner
Specialty Eye
Kirkland, WA / Bellevue,WA
Disclosures:
Alcon, Allergan, Avellino, Bausch + Lomb, BioTissue, CooperVision, EyeVance, Eye Promise Euclid, Horizon Lumenis, Oculus,
Orasis, Oculaphire, Medmont, Novartis, Sun Pharma, TearScience, Thea, Trukara, Valley Contax, Visus Theraputics, Zeiss, and
ZeaVision.
Walter Whitley, OD, MBA, FAAO
Director of Professional Relations and Education
Regional Medical Director – Mid-Atlantic
EyeCare Partners, LLC
Disclosures: Consultant: Alcon, Allergan, Bausch + Lomb, Bruder, I-MED Pharma USA, Kala
Pharmaceuticals, Novartis, Oyster Point Pharma, Regener-Eyes, Santen Pharmaceutical, ScienceBased
Health, Sun Pharma, Tarsus Pharmaceuticals, Théa Pharma; Speakers’ Bureau: Alcon, Allergan, Bausch +
Lomb, Kala Pharmaceuticals, Novartis, Oyster Point Pharma, Santen Pharmaceutical, ScienceBased
Health, Sun Pharma.
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs.
Learners are advised to consult prescribing information for any products discussed. The
information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support
